Author: Ken Dropiewski

Liquidia Corporation Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

MORRISVILLE, N.C., Feb. 02, 2023 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) today announced the grant of inducement stock options exercisable for an aggregate of 10,000 shares of Liquidia’s common stock to newly hired non-executive employees under the Liquidia Corporation 2022 Inducement Plan (the “Inducement Plan”). Each stock option was […]

EDWARDS LIFESCIENCES REPORTS FOURTH QUARTER RESULTS

IRVINE, Calif., Jan. 31, 2023 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2022. Highlights and Outlook Q4 sales grew 1 percent to $1.35 billion; constant currency1 sales grew 7 percent Q4 TAVR sales were flat; constant currency sales grew 5 percent Q4 EPS of $0.65; adjusted1 EPS increased 25 […]

BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2022

MARLBOROUGH, Mass., Feb. 1, 2023 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.242 billion during the fourth quarter of 2022, growing 3.7 percent on a reported basis, 8.7 percent on an operational1 basis and 7.1 percent on an organic2 basis, all compared to the prior year period. Included within organic results is a […]

Neovasc Announces German Reimbursement Renewal

VANCOUVER and MINNEAPOLIS, Feb. 01, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Neovasc, Inc. (“Neovasc” or “the Company”) (NASDAQ , TSX : NVCN) today announced the German Institute for the Hospital Remuneration System (“InEK”) has awarded the Neovasc Reducer™ (“Reducer”), a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation for 2023. New […]

Cadrenal Therapeutics Announces Formation of Scientific Advisory Board

PONTE VEDRA, Fla., Feb. 1, 2023 /PRNewswire/ — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug and Fast Track designations, announced today the formation of its Scientific Advisory Board (SAB) in support of the development of tecarfarin for the prevention of systemic thromboembolism, […]

Conformal Medical Announces Positive One-Year Data from its Left Atrial Appendage Closure Performed Under Conscious Sedation Study

Data to be presented on February 3rd during a Spotlight Session at AF Symposium 2023 NASHUA, N.H., Jan. 31, 2023 /PRNewswire/ — Conformal Medical, Inc. announced today the presentation of the one-year data from the company’s initial left atrial appendage occlusion (LAAO) cases with its novel CLAAS® System in patients under conscious sedation without general anesthesia. […]

Sarnova Announces Leadership Appointments

DUBLIN, Ohio, Jan. 31, 2023 /PRNewswire/ — Sarnova, a leading specialty distributor of healthcare products and services, announced today that Brian LaDuke, currently, President of Sarnova’s Cardiac Response division, has been appointed as the next Chief Executive Officer (CEO) of Sarnova, effective March 1, 2023. Current Sarnova CEO, Jeff Prestel, will transition to a position […]

It Might Be the End of Open-Heart Surgeries: Israeli Biomed Company TruLeaf Medical Will Implant a Mitral Heart Valve via Two Needle Sticks only in a Two-Stage Catheterization Without Surgery

CAESAREA, Israel, Feb. 1, 2023 /PRNewswire/ —  AllMeD Solutions (TASE: ALMD) announced subsidiary TruLeaf Medical’s receipt of the Helsinki Ethics Committee’s approval to conduct clinical trial in human subjects As part of the trial, a prosthetic mitral valve will be implanted via two needle sticks in the groins in a two-stage catheterization procedure without the need for […]

AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS

AMGEN ALSO PROVIDES 2023 GUIDANCE EXCLUDING ANY CONTRIBUTION FROM THE ANNOUNCED ACQUISITION OF HORIZON THERAPEUTICS THOUSAND OAKS, Calif., Jan. 31, 2023 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced financial results for the fourth quarter and full year 2022 versus comparable periods in 2021. “We executed effectively in 2022, delivering strong volume growth, advancing numerous […]